Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma.
Ohguro
Nobuyuki
N
Department of Ophthalmology, Osaka University Medical School E7, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. nohguro@ophthal.med.osaka-u.ac.jp
Hashida
Noriyasu
N
Tano
Yasuo
Y
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005134:Eye Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007267:Injections; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D000069283:Rituximab; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab